DIFFERENT EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN HUMAN ARTERIES AND VEINS

被引:29
作者
YANG, ZH
ARNET, U
VONSEGESSER, L
SIEBENMANN, R
TURINA, M
LUSCHER, TF
机构
[1] UNIV HOSP BASEL,DEPT MED,DIV CLIN PHARMACOL,CH-4031 BASEL,SWITZERLAND
[2] UNIV HOSP BASEL,DEPT RES,VASC RES LAB,CH-4031 BASEL,SWITZERLAND
[3] UNIV HOSP ZURICH,DEPT CARDIOVASC SURG,CH-8091 ZURICH,SWITZERLAND
[4] HEART CTR HIRSLAUDEN,ZURICH,SWITZERLAND
关键词
ANGIOTENSIN; BRADYKININ; ENALAPRILAT; INTERNAL MAMMARY ARTERY; SAPHENOUS VEIN;
D O I
10.1097/00005344-199322005-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The renin-angiotensin system (RAS) participates in the regulation of vascular tone; its effects were studied in human internal mammary artery (IMA) and saphenous vein (SV) suspended in organ chambers for isometric tension recording. The angiotensin-converting enzyme (ACE) inhibitor enalaprilat (10(-7) M) markedly augmented endothelium-dependent relaxations to bradykinin in SV (concentration shift: 10-fold; n = 6; p < 0.005), but not in IMA; in both blood vessels, it had no effect on endothelium-dependent relaxations to acetylcholine. The contractions to angiotensin I (Ang I; 10(-7) M) were markedly inhibited by enalaprilat (10(-7) M) in SV (control: 34 +/- 6% of 100 mM KCl; treatment: 18 +/- 6%; n = 7; p < 0.05) but not in IMA (control: 33 +/-4%; treatment: 30 +/- 6%; n = 7; NS) and abolished by the Ang II receptor antagonist DuP 753 (10(-7) M) in both blood vessels. Ang II (10(-7) M) induced more pronounced contractions than Ang I in IMA (63 +/- 4%) and SV (63 +/- 5%; n = 5-6; p < 0.05 vs. Ang I), which was markedly inhibited by DuP 753 (10(-7) M; IMA: 21 +/- 5%; SV: 32 +/- 5%, p < 0.05). Thus, in SV but not IMA, ACE inactivates bradykinin and thereby blunts endothelium-dependent relaxations to the peptide and converts Ang I to Ang II.
引用
收藏
页码:S17 / S22
页数:6
相关论文
共 27 条
  • [1] BRADYKININ AND ATP STIMULATE L-ARGININE UPTAKE AND NITRIC-OXIDE RELEASE IN VASCULAR ENDOTHELIAL-CELLS
    BOGLE, RG
    COADE, SB
    MONCADA, S
    PEARSON, JD
    MANN, GE
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (02) : 926 - 932
  • [2] BRUNNER HR, 1973, LANCET, V2, P1045
  • [3] BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126
  • [4] ANGIOTENSIN-CONVERTING ENZYME - VASCULAR ENDOTHELIAL LOCALIZATION
    CALDWELL, PRB
    SEEGAL, BC
    HSU, KC
    DAS, M
    SOFFER, RL
    [J]. SCIENCE, 1976, 191 (4231) : 1050 - 1051
  • [5] CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
  • [6] ORAL-ADMINISTRATION OF DUP-753, A SPECIFIC ANGIOTENSIN-II RECEPTOR ANTAGONIST, TO NORMAL-MALE VOLUNTEERS - INHIBITION OF PRESSOR-RESPONSE TO EXOGENOUS ANGIOTENSIN-I AND ANGIOTENSIN-II
    CHRISTEN, Y
    WAEBER, B
    NUSSBERGER, J
    PORCHET, M
    BORLAND, RM
    LEE, RJ
    MAGGON, K
    SHUM, L
    TIMMERMANS, PBMWM
    BRUNNER, HR
    [J]. CIRCULATION, 1991, 83 (04) : 1333 - 1342
  • [7] CLOZEL M, 1991, HYPERTENSION, V18, P37
  • [8] DOHI Y, UNPUB ANGIOTENSIN BL
  • [9] SIGNIFICANCE OF THE VASCULAR RENIN-ANGIOTENSIN PATHWAY
    DZAU, VJ
    [J]. HYPERTENSION, 1986, 8 (07) : 553 - 559